Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 22Terminated 4Recruiting 3Unknown 2No longer available 2Active not recruiting 1

Sponsor Class

NIH 31OTHER 29INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Injections 54Cisplatin 49Paclitaxel 48Carboplatin 43Gemcitabine 38pembrolizumab 36Docetaxel 36Capecitabine 36Drug Therapy 34anlotinib 25Bevacizumab 25Fluorouracil 24icotinib 23Cyclophosphamide 23Oxaliplatin 20fludarabine 18Pemetrexed 17Leucovorin 16Irinotecan 16Temozolomide 14Doxorubicin 14Cetuximab 14camrelizumab 13apatinib 13Nivolumab 13Trastuzumab 12Rituximab 11Fulvestrant 11Etoposide 11tesetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Melphalan × Clear all
NCT01983761 2013-11-18

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Targazyme, Inc.

Phase 1/2 Unknown
25 enrolled
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

NCT01572688 2012-08-02

MM

Shandong Lanjin Pharmaceuticals Co.,Ltd

Phase NA Unknown
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡